As the COVID-19 situation evolves, Sol-Gel is committed to protecting the health, safety and welfare of our employees and their families. We have taken the following steps to help mitigate the spread of the coronavirus:
Business Continuity Plan (BCP) and Disaster Recovery Plan (DRP) were in place ahead of the COVID-19 crisis, and our Information Technology (IT) infrastructure allows recovery in case of a disaster including secured remote access to servers.
Purchase orders were placed to increase our current inventory.
Company is following all restrictions published by the Israeli Ministry of Health (IMOH).
SGT-210 Phase I proof-of-concept clinical study is ongoing subject to IMOH guidelines for COVID-19.
All employees returned to work at our facilities.
Company is taking all measures to ensure the well-being of our employees including frequent on-site cleaning and sanitary measures.
All business travel abroad was canceled and replaced with telecoms and video conferences.
EPSOLAY®️ (encapsulated benzoyl peroxide) & TWYNEO®️ (encapsulated benzoyl peroxide and encapsulated tretinoin)
We completed the clinical programs required for the submission of our NDAs for Epsolay and Twyneo
We also met with the FDA (physically and through telecoms) for pre-NDA meetings
Exhibit batches for Epsolay were produced at full commercial scale and the next production step is the manufacture of the commercial/validation batches
Exhibit batches for Twyneo were produced on a 200kg scale
Our CMOs (Contract Manufacturer Organizations) for Epsolay and Twyneo are open despite COVID-19.
We therefore do not anticipate delays in the submission of the NDAs or the production of the commercial/validation batches for both Epsolay and Twyneo.
This is of course, a dynamic situation which we will be monitoring closely.
Epsolay and Twyneo are registered trademarks of Sol-Gel Technologies Ltd.